LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,777,467
تعداد دریافت فایل اصل مقاله8,803,149
Dehghani, Mehdi, Mokhtari, Samira, Abidi, Hassan, Alipoor, Behnam, Nazer Mozaffari, Mohammad Amin, Sadeghi, Hossein, Mahmoudi, Reza, Nikseresht, Mohsen. (1401). Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients. سامانه مدیریت نشریات علمی, 48(2), 146-155. doi: 10.30476/ijms.2022.92604.2391
Mehdi Dehghani; Samira Mokhtari; Hassan Abidi; Behnam Alipoor; Mohammad Amin Nazer Mozaffari; Hossein Sadeghi; Reza Mahmoudi; Mohsen Nikseresht. "Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients". سامانه مدیریت نشریات علمی, 48, 2, 1401, 146-155. doi: 10.30476/ijms.2022.92604.2391
Dehghani, Mehdi, Mokhtari, Samira, Abidi, Hassan, Alipoor, Behnam, Nazer Mozaffari, Mohammad Amin, Sadeghi, Hossein, Mahmoudi, Reza, Nikseresht, Mohsen. (1401). 'Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients', سامانه مدیریت نشریات علمی, 48(2), pp. 146-155. doi: 10.30476/ijms.2022.92604.2391
Dehghani, Mehdi, Mokhtari, Samira, Abidi, Hassan, Alipoor, Behnam, Nazer Mozaffari, Mohammad Amin, Sadeghi, Hossein, Mahmoudi, Reza, Nikseresht, Mohsen. Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients. سامانه مدیریت نشریات علمی, 1401; 48(2): 146-155. doi: 10.30476/ijms.2022.92604.2391

Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients

Iranian Journal of Medical Sciences
مقاله 6، دوره 48، شماره 2، خرداد 2023، صفحه 146-155    اصل مقاله (924.08 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.92604.2391
نویسندگان
Mehdi Dehghani1؛ Samira Mokhtari2؛ Hassan Abidi3؛ Behnam Alipoor3؛ Mohammad Amin Nazer Mozaffari3؛ Hossein Sadeghi4؛ Reza Mahmoudi3؛ Mohsen Nikseresht* 3
1Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Students Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran
3Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
4Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
چکیده
Background: Circulating microRNAs (miRNAs) can help to predict the chemotherapy response in breast cancer with promising results. The aim of the present study was to investigate the relationships between the miR-199a, miR-663a, and miR-663b expression and chemotherapy response in metastatic breast cancer patients.
Methods: This study is a case-control study performed at Yasuj University of Medical Sciences (2018-2021). The expression levels of miR-663a, miR-663b, and miR-199a in the serum of 25 patients with metastatic breast cancer versus 15 healthy individuals were determined by the real-time polymerase chain reaction method. The response to treatment was followed up in a 24-month period. All patients were treated with second-line medications. Two or more combinations of these drugs were used: gemcitabine, Navelbine®, Diphereline®, Xeloda®, letrozole, Aromasin®, and Zolena®. Statistical analyses were performed in SPSS 21.0 and GraphPad Prism 6 software. The expression levels were presented as mean±SD and analyzed by Student’s t test.
Results: The results and clinicopathological features of patients were analyzed by t test. The statistical analysis showed that miR-663a expression was related to human epidermal growth factor receptor 2 (HER2) status and was significantly lower in the HER2+ than HER2- group (P=0.027). Moreover, the expression of miR-199a and miR-663b was significantly correlated with the response to treatment, in which the expression of miR-199a was higher in the poor-response group (P=0.049), while the higher expression of miR-663b was seen in the good-response group (P=0.009).
Conclusion: These findings state that the high plasma level of miR-199a and the low plasma level of miR-663b may be related to chemoresistance in patients with metastatic breast cancer.
کلیدواژه‌ها
MicroRNAs؛ Breast neoplasms؛ Drug resistance؛ Neoplasm metastasis
سایر فایل های مرتبط با مقاله
مراجع
  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. doi: 10.3322/caac.21708. PubMed PMID: 35020204.
  2. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438-51. doi: 10.3322/caac.21583. PubMed PMID: 31577379.
  3. Danaei M, Haghdoost A, Momeni M. An epidemiological review of common cancers in Iran; a review article. Iranian Journal of Blood and Cancer. 2019;11:77-84.
  4. Fang C, Wang FB, Li Y, Zeng XT. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients. Biomed Pharmacother. 2016;84:1189-93. doi: 10.1016/j.biopha.2016.10.006. PubMed PMID: 27788476.
  5. McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;34:145-55. doi: 10.1007/s10555-015-9551-7. PubMed PMID: 25721950; PubMed Central PMCID: PMCPMC4368851.
  6. Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, et al. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16alpha-18F-Fluoro-17beta-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Oncologist. 2020;25:835-44. doi: 10.1634/theoncologist.2019-0967. PubMed PMID: 32374053; PubMed Central PMCID: PMCPMC7543360.
  7. Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: A new and exciting landscape. Cancer Rep (Hoboken). 2022;5:e1274. doi: 10.1002/cnr2.1274. PubMed PMID: 32881421; PubMed Central PMCID: PMCPMC9124511.
  8. Deblois G, Tonekaboni SAM, Grillo G, Martinez C, Kao YI, Tai F, et al. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discov. 2020;10:1312-29. doi: 10.1158/2159-8290.CD-19-1493. PubMed PMID: 32546577.
  9. Tecza K, Pamula-Pilat J, Lanuszewska J, Butkiewicz D, Grzybowska E. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018;9:9114-36. doi: 10.18632/oncotarget.24148. PubMed PMID: 29507678; PubMed Central PMCID: PMCPMC5823653.
  10. Inoue K, Fry EA. Novel Molecular Markers for Breast Cancer. Biomark Cancer. 2016;8:25-42. doi: 10.4137/BIC.S38394. PubMed PMID: 26997872; PubMed Central PMCID: PMCPMC4790586.
  11. Gao M, Miao L, Liu M, Li C, Yu C, Yan H, et al. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016;7:59714-26. doi: 10.18632/oncotarget.10845. PubMed PMID: 27487127; PubMed Central PMCID: PMCPMC5312343.
  12. Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, et al. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem. 2013;288:10973-85. doi: 10.1074/jbc.M112.434340. PubMed PMID: 23436656; PubMed Central PMCID: PMCPMC3630848.
  13. Mulrane L, McGee SF, Gallagher WM, O’Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013;73:6554-62. doi: 10.1158/0008-5472.CAN-13-1841. PubMed PMID: 24204025.
  14. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014;5:7013-26. doi: 10.18632/oncotarget.2192. PubMed PMID: 25026296; PubMed Central PMCID: PMCPMC4196180.
  15. Deblois G, Tonekaboni SAM, Grillo G, Martinez C, Kao YI, Tai F, et al. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discov. 2020;10:1312-29. doi: 10.1158/2159-8290.CD-19-1493. PubMed PMID: 32546577.
  16. Kim YK. Extracellular microRNAs as Biomarkers in Human Disease. Chonnam Med J. 2015;51:51-7. doi: 10.4068/cmj.2015.51.2.51. PubMed PMID: 26306299; PubMed Central PMCID: PMCPMC4543150.
  17. Oom AL, Humphries BA, Yang C. MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int. 2014;2014:959461. doi: 10.1155/2014/959461. PubMed PMID: 25101302; PubMed Central PMCID: PMCPMC4101974.
  18. Chen J, Shin VY, Siu MT, Ho JC, Cheuk I, Kwong A. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer. 2016;16:887. doi: 10.1186/s12885-016-2916-7. PubMed PMID: 27842518; PubMed Central PMCID: PMCPMC5109692.
  19. Sadakierska-Chudy A. MicroRNAs: Diverse Mechanisms of Action and Their Potential Applications as Cancer Epi-Therapeutics. Biomolecules. 2020;10. doi: 10.3390/biom10091285. PubMed PMID: 32906681; PubMed Central PMCID: PMCPMC7565521.
  20. Feng J, Wang X, Zhu W, Chen S, Feng C. MicroRNA-630 Suppresses Epithelial-to-Mesenchymal Transition by Regulating FoxM1 in Gastric Cancer Cells. Biochemistry (Mosc). 2017;82:707-14. doi: 10.1134/S0006297917060074. PubMed PMID: 28601080.
  21. Li Y, Shan Z, Liu C, Yang D, Wu J, Men C, et al. MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer. Biochemistry (Mosc). 2017;82:474-82. doi: 10.1134/S0006297917040095. PubMed PMID: 28371605.
  22. Xu X, Zhang Y, Jasper J, Lykken E, Alexander PB, Markowitz GJ, et al. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Oncotarget. 2016;7:20381-94. doi: 10.18632/oncotarget.7953. PubMed PMID: 26967387; PubMed Central PMCID: PMCPMC4991462.
  23. Jayaraj R, Nayagam SG, Kar A, Sathyakumar S, Mohammed H, Smiti M, et al. Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis. Cells. 2019;8. doi: 10.3390/cells8101250. PubMed PMID: 31615089; PubMed Central PMCID: PMCPMC6830093.
  24. Zhang HY, Li CH, Wang XC, Luo YQ, Cao XD, Chen JJ. MiR-199 inhibits EMT and invasion of hepatoma cells through inhibition of Snail expression. Eur Rev Med Pharmacol Sci. 2019;23:7884-91. doi: 10.26355/eurrev_201909_18998. PubMed PMID: 31599450.
  25. Michaille JJ, Piurowski V, Rigot B, Kelani H, Fortman EC, Tili E. MiR-663, a MicroRNA Linked with Inflammation and Cancer That Is under the Influence of Resveratrol. Medicines (Basel). 2018;5. doi: 10.3390/medicines5030074. PubMed PMID: 29987196; PubMed Central PMCID: PMCPMC6163211.
  26. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118:2603-14. doi: 10.1002/cncr.26565. PubMed PMID: 22370716; PubMed Central PMCID: PMCPMC3864019.
  27. Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W, et al. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer. Cells. 2019;8. doi: 10.3390/cells8121492. PubMed PMID: 31766744; PubMed Central PMCID: PMCPMC6953059.
  28. Shaffi SK, Galas D, Etheridge A, Argyropoulos C. Role of MicroRNAs in Renal Parenchymal Diseases-A New Dimension. Int J Mol Sci. 2018;19. doi: 10.3390/ijms19061797. PubMed PMID: 29914215; PubMed Central PMCID: PMCPMC6032378.
  29. Chen E, Xu X, Liu R, Liu T. Small but Heavy Role: MicroRNAs in Hepatocellular Carcinoma Progression. Biomed Res Int. 2018;2018:6784607. doi: 10.1155/2018/6784607. PubMed PMID: 29951542; PubMed Central PMCID: PMCPMC5987324.
  30. Svoronos AA, Engelman DM, Slack FJ. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 2016;76:3666-70. doi: 10.1158/0008-5472.CAN-16-0359. PubMed PMID: 27325641; PubMed Central PMCID: PMCPMC4930690.
  31. Davey MG, Lowery AJ, Miller N, Kerin MJ. MicroRNA Expression Profiles and Breast Cancer Chemotherapy. Int J Mol Sci. 2021;22. doi: 10.3390/ijms221910812. PubMed PMID: 34639152; PubMed Central PMCID: PMCPMC8509379.
  32. Mussnich P, Rosa R, Bianco R, Fusco A, D’Angelo D. MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets. 2015;19:1017-26. doi: 10.1517/14728222.2015.1057569. PubMed PMID: 26107137.
  33. Xu X, Zhang L, He X, Zhang P, Sun C, Xu X, et al. TGF-beta plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun. 2018;502:160-5. doi: 10.1016/j.bbrc.2018.05.139. PubMed PMID: 29792857.
  34. Asghariazar V, Sakhinia E, Mansoori B, Mohammadi A, Baradaran B. Tumor suppressor microRNAs in lung cancer: An insight to signaling pathways and drug resistance. J Cell Biochem. 2019;120:19274-89. doi: 10.1002/jcb.29295. PubMed PMID: 31364210.
  35. Nakano M, Kikushige Y, Miyawaki K, Kunisaki Y, Mizuno S, Takenaka K, et al. Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer. Oncogene. 2019;38:780-93. doi: 10.1038/s41388-018-0480-0. PubMed PMID: 30181548.
  36. Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111-23. doi: 10.7150/ijbs.23230. PubMed PMID: 29483830; PubMed Central PMCID: PMCPMC5821033.
  37. Batlle E, Massague J. Transforming Growth Factor-beta Signaling in Immunity and Cancer. Immunity. 2019;50:924-40. doi: 10.1016/j.immuni.2019.03.024. PubMed PMID: 30995507; PubMed Central PMCID: PMCPMC7507121.
  38. Tripathi V, Shin JH, Stuelten CH, Zhang YE. TGF-beta-induced alternative splicing of TAK1 promotes EMT and drug resistance. Oncogene. 2019;38:3185-200. doi: 10.1038/s41388-018-0655-8. PubMed PMID: 30626936; PubMed Central PMCID: PMCPMC6486402.
  39. Hahne JC, Valeri N. Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Front Oncol. 2018;8:226. doi: 10.3389/fonc.2018.00226. PubMed PMID: 29967761; PubMed Central PMCID: PMCPMC6015885.
  40. Li S, Bi T, Wang R, Gao X, Zhou J. Circulating MiR-663 as a novel biomarker for chemo-resistance in breast cancer of neoadjuvant chemotherapy. Int J Clin Exp Med. 2016;9:4002-8.
آمار
تعداد مشاهده مقاله: 895
تعداد دریافت فایل اصل مقاله: 677


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب